Vyome shares rise 18.7% after-hours after securing VT-1953 Phase 3 funding and $1B analyst valuation.

Vyome Holdings Inc. (HIND) surged 18.70% in after-hours trading following news that it has secured all funding requirements for the initial Phase 3 results of its drug candidate VT-1953. An independent analyst recently valued the asset at USD 1 billion upon successful Phase 3 completion, reinforcing investor optimism. The company also announced plans to advance VT-1953 into a pivotal study for FDA approval after reporting positive final Phase 2 data, further solidifying its pipeline prospects. These developments, combined with broader strategic initiatives such as the acquisition of MIT’s Oculo Health and a $3 billion uveitis market opportunity for its topical VT-1908, positioned the stock for a significant after-hours rebound.